Author: Admin

Developer

Ocugen Inc. Set to Join Russell 3000® Index

Posted on by Admin


Ocugen Inc. Set to Join Russell 3000® Index

 

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“As part of the reconstitution process to ensure that new and growing equities are included, we are pleased to be added to the Russell 3000® index which measures the performance of the largest US companies representing approximately 98% of the investable US equity market,” said Sanjay Subramanian, CFO and Head of Corporate Development of Ocugen.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the US and Canadian markets. For more information, please visit http://ocugen.com/

About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit https://www.ftserussell.com/.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corp. Dev.
[email protected]

Media Contact:
LaVoieHealthScience
Lisa DeScenza
[email protected]
+1 978-395-5970

QuickChek – June 16, 2021

Posted on by Admin



Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

Sierra Metals announced the receipt of an Informe Técnico Minero (“ITM”) Permit from the Peruvian Ministry of Energy and Mines

Research, News & Market Data on Sierra Metals

Watch recent presentation from Sierra Metals



Ocugen Inc. Set to Join Russell 3000® Index

Ocugen Inc. announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution

Research, News & Market Data on Ocugen

Watch recent presentation from NobleCon17



electroCore to Join Russell Microcap® Index

electroCore announced the addition of its stock to the broad-market Russell Microcap® Index after its 2021 annual reconstitution

Research, News & Market Data on electroCore



Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

Kratos Defense & Security Solutions announced that it has been named by the federal government as one of the first two Third Party Assessment Organizations (C3PAO)

Research, News & Market Data on Kratos



Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

Lineage Cell Therapeutics announced that Kevin Cook will join as the Company’s Chief Financial Officer, effective June 21, 2021

Research, News & Market Data on Lineage Cell Therapeutics

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

electroCore to Join Russell Microcap® Index

Posted on by Admin


electroCore to Join Russell Microcap® Index

 

ROCKAWAY, NJ, 
June 16, 2021 (GLOBE NEWSWIRE) —  
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap® Index after its 2021 annual reconstitution, effective after the open of trading on 
June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on 
June 4, 2021.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“We are pleased to have been selected to join the Russell Microcap® Index,” said  Brian Posner, Chief Financial Officer of electroCore. “Inclusion in the index should increase our exposure to the investment community and represents an important step in providing continued value for our shareholders.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately 
$10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the impact of electroCore’s inclusion in the Russell Microcap® Index, electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the 
SEC, available at www.sec.gov.


Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

Posted on by Admin


Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

 

CARLSBAD, Calif.–(BUSINESS WIRE)–Jun. 16, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that  Kevin Cook will join as the Company’s Chief Financial Officer, effective 
June 21, 2021.  Mr. Cook will bring more than 20 years of significant strategic, financial, and operational experience to Lineage, with an emphasis in private equity, corporate finance, and investment banking.  Mr. Cook has broad expertise across a range of financial matters and has executed over 
$30 billion of capital raising and corporate development transactions, approximately half of which involved life sciences companies.

“We are excited to welcome Kevin to Lineage as we continue our journey to become a leading cell therapy and cell transplant company,” stated  Brian M. Culley, Lineage CEO. “Kevin is a talented and skilled executive with a proven track record of execution across an array of strategic and financial disciplines. We believe he will be an important addition to the Lineage team and his breadth of experience will contribute significantly to our future success as we advance our product candidates into later stage clinical trials and seek to align strategically with financial and developmental partners to support our further growth.”

Mr. Cook most recently served as Chief Operating Officer of a family office investment firm with an emphasis in the solar energy and infrastructure industries, where he managed existing portfolio companies while pursuing new control investments. From 2012 to 2019, he served as Vice President of Corporate Development and Strategy and Vice President of Business Development for 
Breitburn GP LLC, where he led aggressive growth and diversification efforts for 
Breitburn Energy and affiliates. From 2000 to 2011,  Mr. Cook served as an investment banker for Merrill Lynch & Co., where he advised life sciences companies and other clients across a range of industries in connection with corporate finance and strategic assignments.  Mr. Cook earned his M.B.A. from Northwestern University’s 
Kellogg Graduate School of Management and his B.S. from the 
University of California, Davis.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Mr. Cook’s employment with Lineage and appointment as CFO and the anticipated impact thereof, clinical development of Lineage’s product candidates, and Lineage’s anticipated growth and potential partnerships in furtherance thereof. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
([email protected])
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
([email protected])
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
[email protected]
[email protected]
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

Posted on by Admin


Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

 

SAN DIEGO, 
June 15, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has been named by the federal government as one of the first two CMMC Third Party Assessment Organizations (C3PAO). As a C3PAO, Kratos will be able to conduct CMMC Level 1-3 assessments once the government completes certain preparatory and authorization steps.

The CMMC is a new unified security standard and a certification process developed by the 
U.S. Department of Defense (
DoD) to protect the security of Federal Contract Information (FCI) and Controlled Unclassified Information (CUI) within the Defense Industrial Base (DIB). In accordance with recent updates to DFARS 252.204, the 
Office of the Under Secretary of Defense (OUSD) will begin a phased rollout requiring contractors to achieve CMMC certification. Once the rollout is complete, nearly all companies seeking to respond to 
DoD proposal requests will require CMMC certification.

Kratos has years of robust experience in compliance and certification, risk management and cyber operations, defense and engineering. Services include vulnerability assessments, enterprise security architecture design, application security testing and risk management processes. Kratos cybersecurity services support the development and operation of proactive cybersecurity programs, the development of enterprise cloud security strategies, and the establishment of sound and practical information security architectures tailored to organizational needs.

Mark Williams, Vice President, Kratos Cybersecurity Services explained: “As a member of the DIB Kratos underwent a rigorous assessment by the Defense Industrial Base Cybersecurity Assessment Center, which was a key factor in its early C3PAO authorization by the 
CMMC AB.” Once authorized to begin conducting assessments. Kratos’ Provisional Assessor-led teams will conduct the CMMC assessments that consist of up to four phases. The Planning phase includes assessment plan development and an assessment readiness review. The Assessment phase includes collecting and validating the required Objective Evidence (OE) and generating final results. Presentation of the results occurs in the Report Findings phase. If issues are identified in the Report Findings phase, the Remediation phase is dedicated to evaluating remedial actions taken. Depending on the assessment complexity Kratos estimates that most assessments will be completed in four to six weeks.

Phil Carrai, President of Kratos Space, Training and Cyber Division highlighted the importance of a robust CMMC program. “The recent spate of data breaches affecting both government and commercial organizations underscores the need for more robust security measures to protect critical information. For 
DoD this means increased protection of FCI and CUI data. CMMC will be a critical component of heightened security as all companies will need to pass strict CMMC security assessments before being awarded 
DoD contracts. Kratos is proud to be named one of the first C3PAOs. Our extensive experience in providing advisory and assessment services for compliance frameworks such as FedRAMP and others position us well to support CMMC.”

For more information on Kratos’ CMMC services visit: https://www.kratosdefense.com/cmmc-c3pao.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. Kratos specializes in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Source: Kratos Defense & Security Solutions, Inc.

China Fighting Cost Push Inflation with Metals Reserves

Posted on by Admin


Why are the Chinese Releasing Copper, Aluminum, and Zinc Reserves?

 

When the U.S. Federal Reserve looks to curb producer price inflation, they may take money out of the economy to impact the demand side of the equation. When China is looking to squelch its factory gate inflation, they grow the supply side by releasing reserves of raw materials. At least that is what they announced today (6/16) related to some base metals. 

China is the world’s top metals consumer. A spike in inflation of Chinese made goods would reduce the countries global competitive position. This could lead to decreased exports. For this reason, it’s in the countries best interest to cool the roaring price increases of copper, aluminum, zinc, and others. Prices have been surging this year in reaction to post-pandemic spikes in demand and some speculative buying around the commodities. With today’s announcement, speculators are warned that buying may lead to unintended “pain.” This alone helps to tame prices at the producer or factory stage. 

 

Background/ What is Impacted

Chinese factory gate inflation is the rough equivalent to the U.S. Bureau of Labor Statistics measure of producer price inflation. Factory gate prices jumped to the highest level in over 12 years during May. The higher costs cut into profit margins of final product producers because much of the cost was not able to be passed on to consumers. Global price pressures have been on the rise in many countries as policymakers have been working to revitalize post-Covid-19 economies without unwanted inflation. The balance needed to achieve both has been a growing challenge.

Prices on copper contracts on the Shanghai Futures Exchange and the London Metal Exchange hit record highs in May, after having risen more than 60% since March 2020 as the reaction to the pandemic began to affect global markets. On their website, the Chinese National Food and Strategic Reserves Administration said that it will release reserves for public bid including copper, aluminum, and zinc in batches for nonferrous processing and manufacturing. The sales are not completely unexpected by metals traders as Chinese regulators have been stepping up efforts to cool commodity prices in recent weeks.

 

Take-Away

The Chinese authorities are trying to help support the margins of its manufacturing industry as passing along manufacturing costs to end consumers have not been overly successful. This bodes well for the argument that recent spikes in inflation may be temporary and related to spikes in demand that will level out over time. The Chinese National Food and Strategic Reserves Administration is doing its part to add supplies at a time when demand and speculation of increased demand is at an abnormal peak. The move may help to calm the volatility we have seen in other parts of the world in commodity prices.

Today the Federal Open Market Committee (FOMC) will end their two-day June meeting where U.S. inflation is on their agenda as well. The world markets await being updated on the Fed’s plans for scaling back what are seen as inflationary monetary policies. The Fed statement post meeting typically is made public at 2 pm following the FOMC’s adjournment.

 

Suggested Reading:

The PCE Deflator and the Trimmed PCE Inflation Rate Tell Different Stories

Will Mortgage Forbearance Impact Other Markets?



How Much is a Trillion?

Bond Market Understanding is Now Critical for Stock Investors

 

Virtual Road Show Series – Thursday, Jun 17, @ 1pm EDT

Join Chakana Copper CEO David Kelley for this exclusive corporate presentation, followed by a Q & A session moderated by Mark Reichman, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Sources:

https://www.wsj.com/articles/china-to-release-metal-reserves-in-effort-to-tame-commodities-rally-11623825424?mod=searchresults_pos3&page=1

https://www.wsj.com/articles/copper-falls-to-eight-week-low-on-fear-china-might-release-stockpiles-11623761899?mod=searchresults_pos5&page=1

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

Posted on by Admin


Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

 

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or the “Company”) is pleased to announce the receipt of an Informe Técnico Minero (“ITM”) Permit from the Peruvian Ministry of Energy and Mines. The ITM Permit allows for the construction and operation at a capacity of 3,600 tonnes per day (“TPD”), at the Yauricocha Mine in Peru.

Luis Marchese, CEO of Sierra Metals commented: “I am delighted with the receipt of the ITM permit. The Company may now increase throughput at Yauricocha to 3,600 TPD which represents a 20% increase in throughput. Today’s news will further support the Company in achieving its annual production guidance.

Additionally, we continue focusing on the completion of the Prefeasibility Study at Yauricocha, which examines increasing throughput to 5,500 TPD starting in 2024, as well as on the Prefeasibility Studies for our Mexican operations.”

He concluded: “2021 continues to be an exciting year for the Company as we continue with organic growth plans including significant brownfield and greenfield exploration programs to support future mineral resource and production growth. Management also continues to focus on improving and modernizing our mine operations, increasing operating efficiencies to improve productivity and reduce costs.”

About Sierra Metals

Sierra Metals is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s common shares trade on the Toronto Stock Exchange and the Bolsa de Valores de Lima under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com | Twitter: sierrametals | Facebook: SierraMetalsInc | LinkedIn: Sierra Metals Inc | Instagram: sierrametals

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian and U.S. securities laws related to the Company (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements with respect to the Company’s operations, including anticipated developments in the Company’s operations in future periods, the Company’s planned exploration activities, the adequacy of the Company’s financial resources, and other events or conditions that may occur in the future. Statements concerning mineral reserve and resource estimates may also be considered to constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if and when the properties are developed or further developed. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential” or variations thereof, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in our Annual Information Form dated March 30, 2021 in respect of the year ended December 31, 2020 and other risks identified in the Company’s filings with Canadian securities regulators and the U.S. Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above is not exhaustive of the factors that may affect any of the Company’s forward-looking information. Forward looking information includes statements about the future and are inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

For further information regarding Sierra Metals, please visit www.sierrametals.com or contact:

Mike McAllister
V.P., Investor Relations
Sierra Metals Inc.
+1 (416) 366-7777
Email: [email protected]

Luis Marchese
CEO
Sierra Metals Inc.
+1(416) 366-7777

Source: Sierra Metals Inc.

Advanced Battery Storage Goals of the US Department of Energy

Posted on by Admin 

Image Credit: Charles & Hudson (Flickr)


The U.S. has Solidified its Support for Battery Technology Through 2030

 

The global lithium-based battery market is expected to grow by a factor of 5 to 10 over the next decade. The electric vehicle market often steals the headlines related to the needs of electric power storage systems, but lithium-based batteries are becoming increasingly important for commercial markets, stationary grid-storage systems, national defense, and aviation. Because of the increasing demand for power storage, particularly as it relates to global competition, the U.S. Department of Energy commissioned the Federal Consortium for Advanced Batteries to develop the National Blueprint for Lithium Batteries. The “blueprint” was released this month by the Secretary of Energy. It’s a 24-page document that contains five critical goals to guide collaboration between federal agencies through 2030. Understanding what’s guiding government resources and decisions can benefit investors that seek to benefit from the growth.

 

The 24-page report contains five main goals to achieve the overall vision. Below are the goals further defined by other information pulled from the report. (At the bottom of this article is a link for the full version of The
National Blueprint for Lithium Batteries 2021-2030).

  • Secure access to raw and refined materials and discover alternatives for critical minerals for
    commercial and defense applications.     This goal is set to reduce or eliminate U.S. lithium battery manufacturing dependence on scarce materials such as cobalt and nickel. Securing reliable domestic and foreign sources for critical minerals is a first step toward ultimately replacing the materials in the manufacture of lithium batteries.
  • Support the growth of a U.S. materials-processing base able to meet domestic battery
    manufacturing demand.     At present the US relies on international markets for the processing of most lithium-battery raw materials. The report recommends government involvement in creating greater processing ability within our borders.
  • Stimulate the U.S. electrode, cell, and pack manufacturing sectors. It’s expected that domestic growth and onshoring of cell and pack manufacturing will need ongoing incentives and support for further consumer adoption of EVs. This goal urges developing a federal policy framework that supports manufacturing electrodes, cells, and packs within our borders and encourages incentives to propel demand for lithium-ion batteries.
  • Enable U.S. end-of-life reuse and critical materials recycling at scale and a full
    competitive value chain in the United States.     Recycling lithium-ion cells will help achieve maximize benefit of scarce materials while reducing harmful environmental impacts of mining or disposal. Currently, recyclers face a net end-of-life cost when recycling EV batteries. New more cost efficient methods of testing, transporting, recycling, will be required.
  • Maintain and advance U.S. battery technology leadership by strongly supporting scientific
    R&D, STEM education, and workforce development.     Integral to achieving US leadership is a strong pipeline of R&D, ranging from new electrode and electrolyte materials for next generation lithium-ion batteries, to advances in solid-state batteries, and novel material, electrode, and cell manufacturing methods. The R&D is to be supported by strong intellectual property (IP) protection and rapid movement of innovations from lab to market through public-private R&D partnerships.  

 

Take-Away

The US Department of Energy and the Federal Consortium for the Advancement of Batteries encourage cooperation and coordination across the US Government agencies’ advanced battery efforts to achieve a strong and clean manufacturing and development base. Investors looking to benefit from the newly laid out goals may find putting investment capital in companies focused on recycling, production, or materials procurement may be beneficial as the focus continues to gain momentum and support from Washington. 

 

Suggested Reading:

Can Mining be Green and Sustainable?

Inflation’s Impact on Stocks – Four Scenarios



Why Uranium Prices Have Been Rising

Who Benefits from the American Jobs Plan?

 

 

National
BluePrint for Lithium Batteries 2021-2030

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Sierra Metals Announces Receipt Of Permit Allowing Increase Of Throughput At Its Yauricocha Mine In Peru

Posted on by Admin


Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

 

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or the “Company”) is pleased to announce the receipt of an Informe Técnico Minero (“ITM”) Permit from the Peruvian Ministry of Energy and Mines. The ITM Permit allows for the construction and operation at a capacity of 3,600 tonnes per day (“TPD”), at the Yauricocha Mine in Peru.

Luis Marchese, CEO of Sierra Metals commented: “I am delighted with the receipt of the ITM permit. The Company may now increase throughput at Yauricocha to 3,600 TPD which represents a 20% increase in throughput. Today’s news will further support the Company in achieving its annual production guidance.

Additionally, we continue focusing on the completion of the Prefeasibility Study at Yauricocha, which examines increasing throughput to 5,500 TPD starting in 2024, as well as on the Prefeasibility Studies for our Mexican operations.”

He concluded: “2021 continues to be an exciting year for the Company as we continue with organic growth plans including significant brownfield and greenfield exploration programs to support future mineral resource and production growth. Management also continues to focus on improving and modernizing our mine operations, increasing operating efficiencies to improve productivity and reduce costs.”

About Sierra Metals

Sierra Metals is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s common shares trade on the Toronto Stock Exchange and the Bolsa de Valores de Lima under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com | Twitter: sierrametals | Facebook: SierraMetalsInc | LinkedIn: Sierra Metals Inc | Instagram: sierrametals

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian and U.S. securities laws related to the Company (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements with respect to the Company’s operations, including anticipated developments in the Company’s operations in future periods, the Company’s planned exploration activities, the adequacy of the Company’s financial resources, and other events or conditions that may occur in the future. Statements concerning mineral reserve and resource estimates may also be considered to constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if and when the properties are developed or further developed. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential” or variations thereof, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in our Annual Information Form dated March 30, 2021 in respect of the year ended December 31, 2020 and other risks identified in the Company’s filings with Canadian securities regulators and the U.S. Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above is not exhaustive of the factors that may affect any of the Company’s forward-looking information. Forward looking information includes statements about the future and are inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

For further information regarding Sierra Metals, please visit www.sierrametals.com or contact:

Mike McAllister
V.P., Investor Relations
Sierra Metals Inc.
+1 (416) 366-7777
Email: [email protected]

Luis Marchese
CEO
Sierra Metals Inc.
+1(416) 366-7777

Source: Sierra Metals Inc.

Release – Kratos Named One of the First Cybersecurity Maturity Model Certification Third Party Assessment Organizations

Posted on by Admin


Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

 

SAN DIEGO, 
June 15, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has been named by the federal government as one of the first two CMMC Third Party Assessment Organizations (C3PAO). As a C3PAO, Kratos will be able to conduct CMMC Level 1-3 assessments once the government completes certain preparatory and authorization steps.

The CMMC is a new unified security standard and a certification process developed by the 
U.S. Department of Defense (
DoD) to protect the security of Federal Contract Information (FCI) and Controlled Unclassified Information (CUI) within the Defense Industrial Base (DIB). In accordance with recent updates to DFARS 252.204, the 
Office of the Under Secretary of Defense (OUSD) will begin a phased rollout requiring contractors to achieve CMMC certification. Once the rollout is complete, nearly all companies seeking to respond to 
DoD proposal requests will require CMMC certification.

Kratos has years of robust experience in compliance and certification, risk management and cyber operations, defense and engineering. Services include vulnerability assessments, enterprise security architecture design, application security testing and risk management processes. Kratos cybersecurity services support the development and operation of proactive cybersecurity programs, the development of enterprise cloud security strategies, and the establishment of sound and practical information security architectures tailored to organizational needs.

Mark Williams, Vice President, Kratos Cybersecurity Services explained: “As a member of the DIB Kratos underwent a rigorous assessment by the Defense Industrial Base Cybersecurity Assessment Center, which was a key factor in its early C3PAO authorization by the 
CMMC AB.” Once authorized to begin conducting assessments. Kratos’ Provisional Assessor-led teams will conduct the CMMC assessments that consist of up to four phases. The Planning phase includes assessment plan development and an assessment readiness review. The Assessment phase includes collecting and validating the required Objective Evidence (OE) and generating final results. Presentation of the results occurs in the Report Findings phase. If issues are identified in the Report Findings phase, the Remediation phase is dedicated to evaluating remedial actions taken. Depending on the assessment complexity Kratos estimates that most assessments will be completed in four to six weeks.

Phil Carrai, President of Kratos Space, Training and Cyber Division highlighted the importance of a robust CMMC program. “The recent spate of data breaches affecting both government and commercial organizations underscores the need for more robust security measures to protect critical information. For 
DoD this means increased protection of FCI and CUI data. CMMC will be a critical component of heightened security as all companies will need to pass strict CMMC security assessments before being awarded 
DoD contracts. Kratos is proud to be named one of the first C3PAOs. Our extensive experience in providing advisory and assessment services for compliance frameworks such as FedRAMP and others position us well to support CMMC.”

For more information on Kratos’ CMMC services visit: https://www.kratosdefense.com/cmmc-c3pao.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. Kratos specializes in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Source: Kratos Defense & Security Solutions, Inc.

Release – Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

Posted on by Admin


Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

 

CARLSBAD, Calif.–(BUSINESS WIRE)–Jun. 16, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that  Kevin Cook will join as the Company’s Chief Financial Officer, effective 
June 21, 2021.  Mr. Cook will bring more than 20 years of significant strategic, financial, and operational experience to Lineage, with an emphasis in private equity, corporate finance, and investment banking.  Mr. Cook has broad expertise across a range of financial matters and has executed over 
$30 billion of capital raising and corporate development transactions, approximately half of which involved life sciences companies.

“We are excited to welcome Kevin to Lineage as we continue our journey to become a leading cell therapy and cell transplant company,” stated  Brian M. Culley, Lineage CEO. “Kevin is a talented and skilled executive with a proven track record of execution across an array of strategic and financial disciplines. We believe he will be an important addition to the Lineage team and his breadth of experience will contribute significantly to our future success as we advance our product candidates into later stage clinical trials and seek to align strategically with financial and developmental partners to support our further growth.”

Mr. Cook most recently served as Chief Operating Officer of a family office investment firm with an emphasis in the solar energy and infrastructure industries, where he managed existing portfolio companies while pursuing new control investments. From 2012 to 2019, he served as Vice President of Corporate Development and Strategy and Vice President of Business Development for 
Breitburn GP LLC, where he led aggressive growth and diversification efforts for 
Breitburn Energy and affiliates. From 2000 to 2011,  Mr. Cook served as an investment banker for Merrill Lynch & Co., where he advised life sciences companies and other clients across a range of industries in connection with corporate finance and strategic assignments.  Mr. Cook earned his M.B.A. from Northwestern University’s 
Kellogg Graduate School of Management and his B.S. from the 
University of California, Davis.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Mr. Cook’s employment with Lineage and appointment as CFO and the anticipated impact thereof, clinical development of Lineage’s product candidates, and Lineage’s anticipated growth and potential partnerships in furtherance thereof. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
([email protected])
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
([email protected])
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
[email protected]
[email protected]
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – electroCore to Join Russell Microcap Index

Posted on by Admin


electroCore to Join Russell Microcap® Index

 

ROCKAWAY, NJ, 
June 16, 2021 (GLOBE NEWSWIRE) —  
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap® Index after its 2021 annual reconstitution, effective after the open of trading on 
June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on 
June 4, 2021.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“We are pleased to have been selected to join the Russell Microcap® Index,” said  Brian Posner, Chief Financial Officer of electroCore. “Inclusion in the index should increase our exposure to the investment community and represents an important step in providing continued value for our shareholders.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately 
$10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the impact of electroCore’s inclusion in the Russell Microcap® Index, electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the 
SEC, available at www.sec.gov.


Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Release – Ocugen Inc. Set to Join Russell 3000 Index

Posted on by Admin


Ocugen Inc. Set to Join Russell 3000® Index

 

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“As part of the reconstitution process to ensure that new and growing equities are included, we are pleased to be added to the Russell 3000® index which measures the performance of the largest US companies representing approximately 98% of the investable US equity market,” said Sanjay Subramanian, CFO and Head of Corporate Development of Ocugen.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the US and Canadian markets. For more information, please visit http://ocugen.com/

About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit https://www.ftserussell.com/.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corp. Dev.
[email protected]

Media Contact:
LaVoieHealthScience
Lisa DeScenza
[email protected]
+1 978-395-5970